3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Rectal Neoplasms
5
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thymoma
2
Obesity, Morbid
2
Neoplasms
2
Kidney Neoplasms
2
Genital Diseases, Female
2
Esophageal Neoplasms
2
Uterine Prolapse
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Precancerous Conditions
1
Pelvic Organ Prolapse
1
Pancreatic Neuroendocrine Tumors
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Myasthenia Gravis
1
Menstruation Disturbances
1
Mediastinal Neoplasms
1
Lymphatic Metastasis
1
Interventions
Paclitaxel
326
Carboplatin
318
Bevacizumab
167
Gemcitabine
106
pembrolizumab
100
liposomal doxorubicin
100
Cyclophosphamide
94
Topotecan
93
Cisplatin
89
olaparib
86
niraparib
60
Docetaxel
56
Taxes
52
Doxorubicin
50
Drug Therapy
42
fludarabine
39
Filgrastim
39
Nivolumab
37
Etoposide
32
Specimen Handling
31
Magnetic Resonance Spectroscopy
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Albumin-Bound Paclitaxel
25
durvalumab
24
aldesleukin
24
Hyperthermic Intraperitoneal Chemotherapy
24
Oxaliplatin
23
Biopsy
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ovarian Neoplasms
×
Robotic Surgical Procedures
×
Clear all
NCT07120945
2026-03-06
Embrace Gyn
Medtronic - MITG
Phase NA
Recruiting
70 enrolled